The stock market’s attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of megacap technology companies. Investors looking for value may find one of the more compelling opportunities developing in a different corner of the market. Biotechnology has spent much of the past four years in a bear market. Rising interest rates, weaker venture funding and investor fatigue toward healthcare innovation pushed valuations sharply lower. However, many of the factors that hurt the sector are beginning to reverse. Clinical trial activity is recovering. Global industry sponsored trial starts stabilized at 5,318 in 2024, according to IQVIA, essentially back to the 2019 pre-Covid level of 5,316, after declines in both 2022 and 2023. Activity by U.S. healthcare companies has risen from there, IQVIA said. Funding conditions also are stabilizing and large pharmaceutical companies are approaching a wave of patent expirations that will likely force them to acquire new drugs and technologies, which could also boost stock values. Importantly, investors don’t have to speculate on risky clinical-stage companies to capitalize on the trend. Some of the industry’s highest-quality businesses are trading at discounts to their historical valuations despite maintaining strong competitive positions and long-term growth prospects. While the exact multiples will fluctuate with earnings estimates, all three companies trade at valuations that appear reasonable relative to their competitive advantages, growth prospects and historical trading ranges. The best value: IQVIA If forced to choose a single stock, IQVIA would be my highest-conviction idea . The company sits at the intersection of two powerful trends: growing pharmaceutical research spending and the increasing importance of healthcare data. IQVIA maintains one of the world’s largest healthcare information databases and provides clinical research services to drug developers around the globe. That combination creates a business model that is extraordinarily difficult to replicate. Pharmaceutical companies rely on IQVIA’s data to design studies, identify patients, recruit trial participants, satisfy regulators, and increasingly train AI models. IQV mountain 2016-07-08 IQVIA 10-Year Chart Think of the company as the toll collector on the drug-development highway. What makes the opportunity particularly attractive is valuation. Despite a record backlog, improving demand trends, and significant AI opportunities, the stock trades at a multiple that remains well below historical norms. The market appears to be pricing IQVIA as though biotech research spending will remain permanently subdued. If spending simply returns to normal growth rates, the stock could benefit from both earnings growth and multiple expansion. The recovery play: Danaher Danaher offers a different way to invest in biotech. Rather than developing drugs, the company provides the equipment, filtration systems and manufacturing technologies required to produce them. Through its Cytiva and Pall businesses, Danaher has become one of the most important suppliers to the global biopharmaceutical industry. DHR mountain 2016-07-08 DHR 10-Year Chart The key investment concept is switching costs. When a drug manufacturer validates a production process using a particular filtration platform or bioprocessing system, changing suppliers becomes expensive, time-consuming and potentially risky. Regulatory requirements make those relationships even more durable. As a result, Danaher enjoys one of the strongest installed bases in healthcare. The company’s shares have struggled because biotechnology customers spent much of the past two years working through excess inventory accumulated during the pandemic. Investors have treated that slowdown as evidence of structural weakness. Yet biologic drugs continue to gain share. Cell and gene therapies continue to advance. Pharmaceutical companies continue investing in manufacturing capacity. The industry’s long-term growth drivers remain intact. Danaher appears less like a company facing permanent challenges and more like a dominant franchise emerging from a cyclical downturn. The blue-chip biotech: Vertex Pharmaceuticals Vertex Pharmaceuticals is a true biotechnology company and arguably the highest-quality drug developer in the sector. The company transformed the treatment of cystic fibrosis and now generates substantial free cash flow from a franchise that continues to dominate its market. Unlike many biotech firms, Vertex does not need outside capital to fund its research. That financial strength gives management flexibility to invest aggressively in new opportunities. The company’s pipeline extends well beyond cystic fibrosis, into pain management , kidney disease , gene-editing therapies, and rare diseases. Several of these opportunities could become meaningful growth drivers over the next decade. VRTX mountain 2016-07-08 VRTX 10-Year Chart Vertex is not the cheapest stock among the three recommendations. However, investors will find a company with an exceptional balance sheet, industry-leading profitability, and multiple avenues for growth. In an industry where many businesses are dependent on favorable capital markets, Vertex stands apart as a self-funded innovator. Biotech may be ready to outperform Biotech investors have heard versions of this argument before. The sector has looked inexpensive at various points since 2021, only to disappoint. History explains much of today’s skepticism. The difference now is that several important variables appear to be moving in the same direction. Funding markets are healthier. Clinical activity is improving. AI is accelerating drug discovery and development. Meanwhile, major pharmaceutical companies face increasing pressure to replace revenue that will disappear as key patents expire . Those forces should support greater investment across the biotechnology industry. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
